MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.21
+1.31%Year over year
Reported trailing growth
- Revenue
- +700.0%
- EBITDA
- -10.8%
- EBIT
- -15.7%
- EPS
- -62.5%
- Free cash flow
- -0.2%
- Operating cash flow
- -1.2%
Forward estimates
Based on analyst estimates
- Revenue
- -62.8%
- EBITDA
- -38.5%
- EPS
- -14.0%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026